4SG Stock Chart & Stats
€57.00
-€3.00(-4.29%)
At close: 4:00 PM EDT
€57.00
-€3.00(-4.29%)
Day’s Range― - ―
52-Week Range€25.60 - €82.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€204.07M
Enterprise Value€195.32M
Total Cash (Recent Filing)€30.47M
Total Debt (Recent Filing)€1.39M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Nov 05, 2026EPS Estimate
-1.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding3,273,999
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.15
Price to Sales (P/S)6.06
P/FCF Ratio426.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€150.00Price Target Upside163.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.9
Revenue Forecast (FY)€912.16K
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp 2025 revenue recovery and near-revenue gross profit indicate that approved dermatology products can generate attractive product-level economics. If commercial demand remains stable, this foundation could support reinvestment and improve operating leverage over the next several quarters.
Late-stage PipelineCompletion of the pivotal SGT-610 study moves the lead asset closer to a definitive efficacy and regulatory outcome in a rare disease with limited treatment options. Success could add a differentiated product to the existing dermatology portfolio and broaden long-term growth.
Cash RunwayA substantial cash position extending expected operations into early 2028 gives Sol-Gel time to complete key clinical work without immediate financing pressure. Its lean, outsourced launch strategy may also preserve capital while retaining full product economics in the focused Gorlin market.
Bears Say
Persistent LossesOngoing net and operating losses show that the business has not yet converted its products and pipeline into durable profitability. Continued losses can consume capital, limit strategic flexibility, and make future earnings dependent on sustained execution or additional funding.
Revenue VolatilityThe steep year-on-year revenue decline demonstrates that reported sales can be materially affected by non-recurring transactions rather than underlying product demand alone. Such volatility makes it harder to assess recurring commercial momentum and increases dependence on future launches.
Clinical Execution RiskThe lead growth opportunity remains contingent on Phase 3 results and regulatory approval, so its commercial contribution is not yet established. Delayed, inconclusive, or unfavorable outcomes would leave the company relying more heavily on existing products and earlier-stage pipeline programs.
Sol-Gel Technologies News
4SG FAQ
What was Sol-Gel Technologies’s price range in the past 12 months?
Sol-Gel Technologies lowest stock price was €25.60 and its highest was €82.00 in the past 12 months.
What is Sol-Gel Technologies’s market cap?
Sol-Gel Technologies’s market cap is €204.07M.
When is Sol-Gel Technologies’s upcoming earnings report date?
Sol-Gel Technologies’s upcoming earnings report date is Nov 05, 2026 which is in 8 days.
How were Sol-Gel Technologies’s earnings last quarter?
Sol-Gel Technologies released its earnings results on Aug 20, 2026. The company reported -€1.016 earnings per share for the quarter, beating the consensus estimate of -€2.121 by €1.106.
Is Sol-Gel Technologies overvalued?
According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued.
Does Sol-Gel Technologies pay dividends?
Sol-Gel Technologies does not currently pay dividends.
What is Sol-Gel Technologies’s EPS estimate?
Sol-Gel Technologies’s EPS estimate is -1.86.
How many shares outstanding does Sol-Gel Technologies have?
Sol-Gel Technologies has 3,273,999 shares outstanding.
What happened to Sol-Gel Technologies’s price movement after its last earnings report?
Sol-Gel Technologies reported an EPS of -€1.016 in its last earnings report, beating expectations of -€2.121. Following the earnings report the stock price went down -1.504%.
Which hedge fund is a major shareholder of Sol-Gel Technologies?
Currently, no hedge funds are holding shares in DE:4SG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sol-Gel Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€150.00 (163.16% Upside)
€150.00 (163.16% Upside)
Blogger Sentiment
Neutral
DE:4SG Sentiment 50%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth €3.4M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
78.53%
12-Months-Change
Fundamentals
Return on Equity
-44.05%
Trailing 12-Months
Asset Growth
36.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sol-Gel Technologies
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
4SG Stock 12 Month Forecast
Average Price Target
€150.00
▲(163.16% Upside)
Technical Analysis
Insight Molecular Diagnostics
―
Ovid Therapeutics
―
Shattuck Labs
―
Surrozen
―
Metagenomi, Inc.
―